Randomized, Double-Blind Trial of MP29-02 Nasal Spray Compared to Placebo, Azelastine Hydrochloride Nasal Spray, and Fluticasone Propionate Nasal Spray in the Treatment of Patients With Seasonal Allergic Rhinitis.

Trial Profile

Randomized, Double-Blind Trial of MP29-02 Nasal Spray Compared to Placebo, Azelastine Hydrochloride Nasal Spray, and Fluticasone Propionate Nasal Spray in the Treatment of Patients With Seasonal Allergic Rhinitis.

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Nov 2015

At a glance

  • Drugs Azelastine/fluticasone-propionate (Primary) ; Azelastine; Fluticasone propionate
  • Indications Seasonal allergic rhinitis
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 23 Oct 2015 According to the media release of Meda Pharmaceuticals, based on the data from this and other two trials (CTP: 32910 and 43617) Dymista nasal spray (azelastine hydrochloride/fluticasone propionate) was approved by Health Canada for the symptomatic treatment of moderate-to-severe seasonal allergic rhinitis.
    • 06 Mar 2012 Key secondary endpoint results presented at the 68th Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
    • 05 Mar 2012 Results from this trial were presented at the American Academy of Allergy, Asthma and Immunology (AAAAI), according to a Meda media release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top